Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹893Cr
Rev Gr TTM
Revenue Growth TTM
20.81%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

HERANBA
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | | -24.0 | 0.9 | 8.6 | -0.9 | 7.7 | 3.1 | 13.9 | 29.8 | 52.7 | 19.3 | -11.7 |
| 240 | 279 | 380 | 275 | 246 | 256 | 378 | 329 | 349 | 421 | 473 | 289 |
Operating Profit Operating ProfitCr |
| 7.9 | -1.5 | 10.4 | 8.1 | 4.8 | 13.6 | 13.6 | 3.7 | -4.3 | 6.9 | 9.4 | 4.1 |
Other Income Other IncomeCr | 3 | 6 | 2 | 2 | 5 | 1 | 3 | 0 | 3 | 13 | -3 | 4 |
Interest Expense Interest ExpenseCr | 3 | 2 | 2 | 3 | 5 | 5 | 6 | 6 | 14 | 12 | 12 | 12 |
Depreciation DepreciationCr | 6 | 6 | 6 | 6 | 8 | 13 | 14 | 14 | 16 | 21 | 26 | 26 |
| 15 | -6 | 38 | 17 | 4 | 24 | 43 | -7 | -41 | 11 | 8 | -22 |
| 3 | -1 | 11 | 3 | 4 | 7 | 5 | 3 | 1 | 5 | 10 | 2 |
|
Growth YoY PAT Growth YoY% | | -116.8 | -42.9 | 10.1 | -106.5 | 396.3 | 40.0 | -174.5 | -5,608.2 | -62.0 | -105.7 | -126.0 |
| 4.3 | -2.0 | 6.3 | 4.7 | -0.3 | 5.6 | 8.6 | -3.0 | -12.4 | 1.4 | -0.4 | -7.8 |
| 2.8 | -1.4 | 6.7 | 3.5 | -0.1 | 4.2 | 9.5 | -2.5 | -10.4 | 1.5 | 0.4 | -5.8 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | -4.7 | 12.1 | 14.2 |
| 1,163 | 1,180 | 1,312 | 1,532 |
Operating Profit Operating ProfitCr |
| 11.8 | 6.1 | 7.0 | 4.8 |
Other Income Other IncomeCr | 12 | 14 | 8 | 17 |
Interest Expense Interest ExpenseCr | 8 | 12 | 31 | 50 |
Depreciation DepreciationCr | 23 | 26 | 57 | 88 |
| 138 | 52 | 18 | -44 |
| 33 | 18 | 16 | 17 |
|
| | -66.9 | -93.5 | -2,808.0 |
| 7.9 | 2.7 | 0.2 | -3.8 |
| 26.1 | 8.7 | 0.8 | -14.3 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 40 | 40 | 40 | 40 |
| 770 | 803 | 801 | 802 |
Current Liabilities Current LiabilitiesCr | 339 | 591 | 860 | 1,230 |
Non Current Liabilities Non Current LiabilitiesCr | 13 | 36 | 103 | 104 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 844 | 840 | 1,033 | 1,386 |
Non Current Assets Non Current AssetsCr | 318 | 639 | 780 | 798 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 107 | 101 |
Investing Cash Flow Investing Cash FlowCr | -241 | -239 |
Financing Cash Flow Financing Cash FlowCr | 62 | 152 |
|
Free Cash Flow Free Cash FlowCr | -145 | -137 |
| 310.7 | 4,502.2 |
CFO To EBITDA CFO To EBITDA% | 139.5 | 103.5 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 1,118 | 1,134 | 852 |
Price To Earnings Price To Earnings | 10.7 | 32.5 | 276.4 |
Price To Sales Price To Sales | 0.8 | 0.9 | 0.6 |
Price To Book Price To Book | 1.4 | 1.4 | 1.0 |
| 7.0 | 16.4 | 11.7 |
Profitability Ratios Profitability Ratios |
| 33.1 | 31.1 | 33.0 |
| 11.8 | 6.1 | 7.0 |
| 7.9 | 2.7 | 0.2 |
| 16.1 | 6.4 | 4.1 |
| 12.9 | 4.1 | 0.3 |
| 9.0 | 2.3 | 0.1 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Heranba Industries Limited (HIL) is a leading Indian agrochemical company with fully integrated operations across the synthetic pyrethroid and broader agrochemical value chain. Founded in 1992 (note: alternate references cite 1994) by technocrats Sadashiv K. Shetty and Raghuram K. Shetty in Vapi, Gujarat, the company has evolved from an intermediate manufacturer into a vertically integrated player producing **intermediates, technical-grade agrochemicals, branded formulations, and public health products**. HIL operates seven manufacturing and packaging facilities across Gujarat (Vapi, Saykha, Sarigam) and Maharashtra (Boisar), serving over 225 international customers and maintaining a strong domestic presence via a network of 10,000+ dealers across 20 Indian states and UTs.
---
### **Core Business Segments & Product Portfolio**
Heranba operates across three primary business verticals:
1. **Domestic Sales of Technicals**
2. **Export Sales of Technicals**
3. **Branded Formulations (Domestic)**
#### **Key Products:**
- **Insecticides:** Synthetic pyrethroids (e.g., Cypermethrin, Deltamethrin, Alpha Cypermethrin, Lambda Cyhalothrin, Permethrin), Neonicotinoids, Organophosphorus
- **Herbicides:** Glyphosate, Metribuzin, Bispyribac Sodium, and new off-patent molecules
- **Fungicides:** Tricyclazole, Hexaconazole, and developing products for rice, fruits, and vegetables
- **Public Health Products:** Larvicides and insecticides marketed under brands like *Alpha Shakti-5WP*, *Temper EC*, and *Deltaflow*
The company is recognized as **one of India’s largest producers of synthetic pyrethroids**, known for their eco-friendly profile compared to older chemical classes.
---
### **Operational Strength & Manufacturing Capabilities**
- **Manufacturing Footprint:** 7 integrated facilities (as of Nov 2025) across Vapi, Saykha, and Sarigam (Gujarat), with a combined area of 124,970 sq. m. and ~72,000 sq. m. available for expansion.
- **Production Capacity (FY25):**
- **Intermediates & Technicals:** 26,700 MTPA (more than doubled since FY21)
- **Formulations:** 30,000 MTPA
- **Reactor Base:** Over 384 reactors across facilities, enabling advanced processes like hydrogenation, halogenation, esterification, and diastereoselective synthesis.
- **Backward Integration:** In-house production of key intermediates such as CMAC, MPBAL, and Bromobenzene, enabling cost control and supply chain security.
- **Recent Expansions (FY25):**
- Phase I of Saykha Unit commissioned in April 2025
- Phase II of Sarigam Unit commissioned in July 2025
- These projects significantly boosted AI capacity and supported diversification into herbicides and fungicides.
---
### **Revenue Mix & Market Diversification (FY25)**
- **48%** of revenue from **domestic branded formulations**
- **8%** from **formulation exports**
- **29%** from **technicals exports**
- The formulations business (domestic + export) now contributes **>56% of total revenue**, indicating a strategic shift toward higher-margin products.
- **41–42% of revenue** comes from exports (as of FY22–FY24), with a long-term target of **60% export mix**.
- Top 10 customers account for ~15% of revenue (FY24), indicating a diversified customer base.
---
### **R&D, Innovation & Regulatory Edge**
- **R&D Investment:** ₹6.45 crore in FY25
- **R&D Infrastructure:** 3 in-house centers recognized by DSIR; labs certified under ISO 9001, ISO 14001, and NABL (ISO/IEC 17025)
- **Key Instruments:** HPLC, GC, UV-Vis, electron microscopes, bead mills, air jet mills, fluidized bed dryers
- **Recent R&D Output (FY25):**
- 5 new herbicides (3 launched)
- 4 fungicides (3 launched)
- 3 insecticides (2 piloted and launched in select markets)
- **Product Registrations:**
- **1,084 cumulative registrations** across **54+ countries** (up from 892 in FY23)
- **183 products in pipeline**, with focus on regulated markets
- **Strategic Priority:** Securing registrations in **regulated markets (USA, Europe, Brazil)**, with early approvals received in the U.S. and additional filings underway.
---
### **Global Expansion & Market Access**
- **Geographic Presence:** Operates in **>75 countries**, including developed markets (U.S., Europe), emerging Asia (Bangladesh, Indonesia, Vietnam, China), CIS, Middle East, Africa, and Latin America.
- **Strategic Entry into Developed Markets:**
- Successfully launched first insecticide in U.S. in Oct 2021.
- Plans to generate **$25 million in U.S. sales** in the coming years.
- Targeting $50 million long-term opportunity in U.S. market.
- Developing molecules tailored for the U.S., Europe, and Brazil.
- **Distribution Model:**
- **Exports:** Sold via international partners who register and brand products locally (B2B technicals and formulations).
- **Domestic:** Direct-to-farmer via 10,000+ dealers and 31 stock depots.
---
### **Key Strategic Initiatives (FY25–FY27)**
1. **Entry into CRAMS/CRO/CDMO Space:**
- Achieved through the **acquisition of Daikaffil Chemicals India Limited** (Tarapur, Maharashtra), providing land, infrastructure, and capabilities.
- A new **R&D and pilot plant center** with **15 reactors** is under development; Phase I scheduled for **completion by Q1 FY27**.
- Investment: ₹50 crore allocated for Phase I.
- Will offer end-to-end services in **agrochemicals, pharmaceuticals, biopharmaceuticals, plant nutrition, and specialty chemicals**.
- Plans to hire **60 new scientists** in synthetic chemistry, analytical R&D, and formulation development.
2. **Capacity Expansion & CAPEX:**
- Over ₹1,200 crore invested in CAPEX since FY22.
- Expansion at Sarigam and Saykha facilities has more than doubled AI capacity.
- Future CAPEX planned for fermentation technology, performance chemicals, and GLP-certified facilities (Phase II).
3. **Diversification Beyond Pyrethroids:**
- Historically ~70–75% insecticide-focused, but now shifting toward **50:50 split between pyrethroids and non-pyrethroids**, expected to become **40:60** in favor of other agrochemicals within 2 years.
- New capacity supports fungicides and herbicides commercialization.
4. **Focus on Regulated Markets:**
- Actively commercializing off-patent agrochemicals in the U.S. and Europe.
- Regulatory dossiers prepared internally or through partners.
- Multiple pyrethroid (lambda cyhalothrin, deltamethrin) and herbicide registrations obtained or in pipeline in U.S. and EU.
---
### **Management & Leadership Updates (Nov 2025)**
- Appointed a **new Vice President of Sales & Marketing** based in Mumbai with **25+ years of experience** in the agri-industry.
- New incumbent holds **MBA in Marketing** and **B.Sc. in Agriculture (Hons.)**.
- Core expertise: **Go-to-market strategies, new product launches, commercial leadership** in crop protection and nutrition.
- This appointment signals a renewed focus on scaling domestic branded formulations and enhancing commercial execution.